Significant Applications in Health Care, Food Quality and Safety and More Know Labs, Inc. (NYSE:KNW) is pleased to announce that it has completed extensive research in its laboratory utilizing its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify changes in pH levels in real time. The research has been submitted for peer reviewed publication. The research is available for review today here on the Company's website at www.knowlabs.co. An abstract of the paper states, "We describe an experiment in which we employ a radio frequency sensor to measure pH changes in a liquid solution. The experiment is novel in a few ways. First, the sensor does not have cont
The company to meet with potential strategic partners to discuss collaborating on advancing clinical research of its non-invasive blood glucose monitor Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology with its Radio Frequency Dialectic Spectroscopy (RFDS) platform, today announced the company will be attending The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair in Amsterdam, Netherlands on March 19-22, 2025. The Company will share updates on the development of its non-invasive blood glucose monitor, since last year's conference, and discuss opportunities for collaboration and partnership
Know Labs, Inc. (NYSE:KNW, now OTC Pink Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today the cancellation of the Special Meeting of Stockholders previously scheduled for March 7, 2025 (Special Meeting), which was intended to seek approval for a reverse stock split. The Company's decision to cancel the Special Meeting comes after the Company announced a 1 for 40 reverse stock split of its authorized and issued and outstanding shares of common stock on February 18, 2025, which became effective February 19, 2025, and did not require the approval of stockholders. About Know Labs Technology Licensing (KTL
Know Labs, Inc. (NYSE:KNW, now OTC Pink Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today a 1 for 40 reverse stock split of its authorized and issued and outstanding shares of common stock. The reverse stock split was announced on February 18, 2025. The reverse stock split will be effective as of the morning of February 19, 2025, and the Company's common stock will trade on the OTC Pink Market on a post-split basis at the beginning of trading on the same date temporarily, for a period of twenty days, under the trading symbol "KNWND." As previously announced, effective January 29, 2025, FINRA's Departmen
Know Labs, Inc. (NYSE:KNW, now OTC Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and diverse other fields of use through its newly initiated Know Labs Technology Licensing (KTL) initiative, today reported financial results for the first quarter of the fiscal year 2025. Financial Highlights: In Q1 FY 2025, Know Labs reported a net loss of $4.67 million dollars, compared to a net loss of $3.45 million dollars in Q1 FY 2024, an increase in net loss of 35.4%. This translates to earnings per share of a loss of $0.04, unchanged from the prior year earnings per share loss
Know Labs, Inc. (NYSE:KNW, now OTC Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and diverse other fields of use through its newly initiated Know Labs Technology Licensing (KTL) initiative, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2025 ended on December 31, 2024, on February 14, 2025, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at https://ir.knowlabs.co, beginning at 1:15 pm PT. The webcast will also be available for replay at the company's website. For m
Know Labs Continues Trading as "KNWN" on the OTC Market Know Labs, Inc. (NYSE:KNW, now OTC Markets: KNWN)), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today it has filed an appeal of the NYSE American's commencement of proceedings to delist Know Labs from its exchange. The Company will continue working on certain curative actions to regain compliance to maintain its listing while it awaits its appeal to the Listings Qualifications Panel of the Exchange. The Company's stock will be suspended from trading on the NYSE American during this time. NYSE Regulation is commencing delisting proceedings in connection with its d
Know Labs Trading as "KNWN" on the OTC Market Know Labs, Inc. (NYSE:KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today it is working on certain curative actions to regain compliance to maintain its listing and appeal the NYSE's determination to delist its common stock to the Listings Qualifications Panel of the Exchange. The company's stock will be suspended from trading on the NYSE American during this time. NYSE Regulation is commencing delisting proceedings in connection with its determination, announced today, that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE Americ
Company to Drive Monetization of its Patented Platform Technology Across Diverse Industries Know Labs, Inc. (NYSE:KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), is proud to announce the formation of its new business unit, Know Labs Technology Licensing, (KTL). Modeled after the successful Qualcomm Technology Licensing (QTL) framework, KTL will be dedicated to licensing Know Labs' robust intellectual property (IP) portfolio to corporate partners, academic institutions and research organizations, fostering innovation and accelerating the adoption of RFDS platform technology across a broad range of industries and the academic a
Know Labs, Inc. (NYSE:KNW) (the "Company"), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a registered direct offering with gross proceeds to the company of $300K before deducting placement agent fees and other estimated expenses payable by the Company. This was a unit offering comprised of one share of stock and one warrant. The purchase price of the unit was $0.24 a share and the warrant is exercisable at $0.24. The warrants will expire on the fifth anniversary of the warrant issuance. The warrants also have a cashless exercise option in certain circumstances. This was a registered direct offering priced at-the-market under NYSE Ameri
SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)
SC 13D - KNOW LABS, INC. (0001074828) (Subject)
SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)
SC 13G - KNOW LABS, INC. (0001074828) (Subject)
SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)
SC 13G/A - KNOW LABS, INC. (0001074828) (Subject)
10-Q - KNOW LABS, INC. (0001074828) (Filer)
8-K - KNOW LABS, INC. (0001074828) (Filer)
8-K - KNOW LABS, INC. (0001074828) (Filer)
DEF 14A - KNOW LABS, INC. (0001074828) (Filer)
PRE 14A - KNOW LABS, INC. (0001074828) (Filer)
424B5 - KNOW LABS, INC. (0001074828) (Filer)
8-K - KNOW LABS, INC. (0001074828) (Filer)
8-K - KNOW LABS, INC. (0001074828) (Filer)
8-K - KNOW LABS, INC. (0001074828) (Filer)
424B5 - KNOW LABS, INC. (0001074828) (Filer)
Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share
Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te
Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn
Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app
New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p
Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg
Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the establishment of a Scientific Advisory Board (SAB) comprised of distinguished researchers, innovators and experts in medical technology and human health. SAB members will advise the company and its strategic partners on advancing the company's progress in algorithm refinement, device development, clinical trial design and research publication strategy. SAB members will be working alongside Know Labs' current Medical and Regulatory Advisory Board members who have been supporting the team since 2020 and will be pivotal in helping Know Labs accelerate the development and deliver
4/A - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)
4 - KNOW LABS, INC. (0001074828) (Issuer)